E Fund Management Co. Ltd. Makes New $517,000 Investment in Vaxcyte, Inc. $PCVX

E Fund Management Co. Ltd. acquired a new stake in shares of Vaxcyte, Inc. (NASDAQ:PCVX) in the second quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor acquired 8,898 shares of the company’s stock, valued at approximately $517,000.

A number of other hedge funds also recently bought and sold shares of PCVX. Royal Bank of Canada boosted its holdings in shares of Vaxcyte by 115.2% in the first quarter. Royal Bank of Canada now owns 29,471 shares of the company’s stock worth $1,113,000 after buying an additional 15,774 shares during the period. Cubist Systematic Strategies LLC acquired a new stake in shares of Vaxcyte during the first quarter valued at approximately $219,000. Caxton Associates LLP acquired a new stake in shares of Vaxcyte during the first quarter valued at approximately $226,000. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC lifted its position in shares of Vaxcyte by 8.7% in the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 513,998 shares of the company’s stock valued at $19,409,000 after acquiring an additional 41,034 shares in the last quarter. Finally, Cetera Investment Advisers lifted its position in shares of Vaxcyte by 13.8% in the 2nd quarter. Cetera Investment Advisers now owns 7,681 shares of the company’s stock valued at $250,000 after acquiring an additional 932 shares in the last quarter. 96.78% of the stock is owned by hedge funds and other institutional investors.

Vaxcyte Stock Down 3.1%

Shares of NASDAQ:PCVX opened at $61.34 on Friday. The firm has a fifty day moving average of $56.12 and a two-hundred day moving average of $55.76. The firm has a market capitalization of $9.13 billion, a P/E ratio of -8.04 and a beta of 1.23. Vaxcyte, Inc. has a 12-month low of $29.87 and a 12-month high of $65.00.

Vaxcyte (NASDAQ:PCVX) last announced its quarterly earnings data on Wednesday, August 5th. The company reported ($1.97) earnings per share (EPS) for the quarter, topping the consensus estimate of ($2.06) by $0.09. During the same period in the previous year, the business earned ($1.22) EPS. Equities research analysts expect that Vaxcyte, Inc. will post -7.6 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

Several equities analysts have weighed in on PCVX shares. Wall Street Zen upgraded shares of Vaxcyte from a “strong sell” rating to a “sell” rating in a research report on Saturday, August 8th. Weiss Ratings restated a “sell (d-)” rating on shares of Vaxcyte in a report on Monday, July 6th. Finally, Zacks Research raised Vaxcyte from a “strong sell” rating to a “hold” rating in a research report on Wednesday, August 12th. Five research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, Vaxcyte presently has an average rating of “Moderate Buy” and a consensus price target of $86.00.

Insider Transactions at Vaxcyte

In related news, insider Harpreet S. Dhaliwal sold 17,000 shares of the business’s stock in a transaction that occurred on Wednesday, August 5th. The stock was sold at an average price of $55.00, for a total value of $935,000.00. Following the completion of the sale, the insider owned 76,756 shares of the company’s stock, valued at approximately $4,221,580. The trade was a 18.13% decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Grant Pickering sold 2,000 shares of the stock in a transaction that occurred on Monday, July 27th. The stock was sold at an average price of $55.65, for a total value of $111,300.00. Following the completion of the transaction, the chief executive officer owned 133,215 shares in the company, valued at $7,413,414.75. This represents a 1.48% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 120,646 shares of company stock valued at $6,570,810 over the last 90 days. Company insiders own 3.30% of the company’s stock.

About Vaxcyte

Vaxcyte, Inc (NASDAQ: PCVX) is a clinical-stage biotechnology company focused on developing a new generation of preventive vaccines aimed at combating serious bacterial diseases. Headquartered in San Carlos, California, Vaxcyte leverages proprietary conjugation technologies to design and manufacture multivalent vaccines targeting pathogens for which there remain significant unmet medical needs. The company’s platform is intended to streamline the production of conjugate vaccines by improving antigen presentation and broadening strain coverage compared with conventional approaches.

Vaxcyte’s lead candidate, VAX-24, is a 24-valent pneumococcal conjugate vaccine designed to protect against 24 serotypes of Streptococcus pneumoniae.